胡卓伟 - 中国医学科学院药物研究所 -

个人简介

1976年毕业于湖南医科大学医疗系并从事临床工作三年。1982年毕业于湖南医科大学硕士研究班并在该院从事临床工作三年。1985年到美国加州大学作博士后访问学者。1986年进入斯坦福大学继续临床药理博士后研究。1992年获斯坦福大学分子细胞生理学专业博士学位，随后在斯坦福大学工作长达12年，历任研究科学家、高级科学家、高级副研究员和高级研究员，并从1995年起担任辉瑞公司临床前研究顾问多年。2004年回国后在中国医学科学院北京协和医学院药物研究所建立了分子免疫药理实验室，现为中国医学科学院&北京协和医学院药物研究所研究员、博士生导师、北京协和医学院特聘教授、国家人事部"高层次留学人才回国资助人员"，教育部"长江学者特聘教授"，2015年获得国务院颁发的政府特殊津贴。

研究领域

主要研究领域包括免疫生物学和免疫药理、心血管生物学和心血管药理、分子细胞生物学和分子药理、受体和信号传导通道的调节机制。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

1. Hua F, Hu ZW*. TRIB3-P62 interaction, diabetes and autophagy. Oncotarget, 2015, [Epub ahead of print]. 2. Hua F, Li K, Yu JJ, Hu ZW*. The TRIB3-SQSTM1 interaction mediates metabolic stress-promoted tumorigenesis and progression via suppressing autophagic and proteasomal degradation. Autophagy, 2015, 11:1929- 1931. 3. Hua F, Li K, Yu JJ, Lv XX, Yan J, Zhang XW, Sun W, Lin H, Shang S, Wang F, Cui B, Mu R, Huang B, Jiang JD, Hu ZW*. TRB3 links insulin/IGF to tumour promotion by interacting with p62 and impeding autophagic/ proteasomal degradations. Nat Commun, 2015, 13;6:7951. 4. Yu JM, Sun W, Hua F, Xie J, Lin H, Zhou DD, Hu ZW*. BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett, 2015, 365:190-200. 5. Li K, Lv XX, Hua F, Lin H, Sun W, Cao WB, Fu XM, Xie J, Yu JJ, Li Z, Liu H, Han MZ, Hu ZW*,Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a toll-like receptor 2-mediated cell-penetrating peptide. Intl J Cancer, 2014, 134:692-702. 6. Wang XX, Lv XX, Wang JP, Yan HM, Wang ZY, Liu HZ, Fu XM, Hu ZW*. Blocking TLR2 activity diminishes and stabilizes advanced atherosclerotic lesions in apolipoprotein E-deficient mice. Acta Pharmacol Sin, 2013, 34:1025-1035. 7. Lv XX, Wang XX, Li K, Wang ZY, Li Z, Lv Q, Fu XM, and Hu ZW*，Rupatadine Protects against Pulmonary Fibrosis by Attenuating PAF-Mediated Senescence in Rodents. PLoS One, 2013, 8:e68631. 8. Lin H, Liu XB, Yu JJ, Hua F, Hu ZW*. Antioxidant N-acetylcysteine attenuates hepatocarcinogenesis by inhibiting ROS/ER stress in TLR2 deficient mouse. PLoS One, 2013, 8:e74130. 9. Wang ZY, Lin H, Hua F and Hu ZW*. Repairing DNA damage by XRCC6/KU70 reverses TLR4-deficiency-worsened HCC development via restoring senescence and autophagic flux. Autophagy, 2013, 9:925-7. 10. Du D, Yan J, Ren JH, Lv HN, Li Y, Xu S, Wang Y, Ma SG, Qu J, Tang WB, Hu ZW*, Yu SS*. Synthesis, Biological Evaluation, and Docking Studies of Glycyrrhizin Derivatives as Potent High-Mobility Group Box-1 Inhibitors with Anti- Heart Failure Activity in Vivo. J Med Chem, 2013, 56: 97-108, 11. Wang ZY, Yan J, Lin H, Hua F, Wang XX, Liu H, Lv XX, Yu JJ, Mi S, Wang JP, Hu ZW*. TLR4 activity protects against hepatocellular tumorigenesis and progression via regulating the expression of DNA repair protein Ku70. Hepatology, 2013, 57:1869-81. 12. Liu H, Mi S, Li Z, Hua F and Hu ZW*. Interleukin 17A inhibits autophagy through activation of PIK3CA to interrupt the GSK3B-mediated degradation of BCL2 in lung epithelial cells. Autophagy, 2013, 9:730-42. 13. Lin H, Yan J, Wang ZY, Hua F, Yu JJ, Sun W, Li K, Liu H, Yang HZ, Lv Q, Xue JF, and Hu ZW*. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in toll-like receptor 2-deficient mouse model. Hepatology, 2013, 57:171-182. 14. Sun W, Hu ZW*. Making T cells functional: a new solution for the athymic BMT recipients. Acta Pharmacol Sin, 2013, 34:189-190. 15. Lin H#, Hua F, and Hu ZW*. Autophagic flux, supported by Toll-like receptor 2 activity, defends against the carcinogenesis and progression of hepatocellular carcinoma. Autophagy, 2012, 8:1859-61.. 16. Lv Q, Wang W, Xue JF, Hua F, Mu R, Lin H, Yan J, Lv XX, Chen XG, Hu ZW*. DEDD interacts with class III PI-3-kinase to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res, 2012, 72: 3238-50. 17. Lv Q#, Hua F, and Hu ZW*. DEDD, a novel tumor repressor reverses epithelial-mesenchymal transition by activating selective autophagy. Autophagy, 2012, 8:12-14. 18. Ma YG, Zhang XW#, Mi S, Cai WF, Yan HM, Wang QQ, Wang ZY, Yan J, Wang JP, Wang XX，Lv XX, Yang HZ, Fan GC, Hu ZW*. Toll-Like Receptor (TLR) 2 and TLR4 differentially Regulate Doxorubicin Induced Cardiomyopathy in Mice. PLoS One, 2012, 7:e40761. 19. Sun W, Xie J, Lin H, Mi S, Li Z, Hua F, and Hu ZW*. A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies. Protein Expr Purif, 2012, 83:21-29. 20. Zhu CJ*, Wang QQ, Zhou JL, Liu HZ, Hua F, Yang HZ, and Hu ZW*. The mineralocorticoid receptor-p38MAPK-NFκB or ERK-Sp1 signal pathways mediate aldosterone-stimulated inflammatory and profibrotic responses in rat vascular smooth muscle cells. Acta Pharmacol Sin, 2012, 33:873-878.